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Abstract : The development of new and useful pharmaceutical drugs is essential in order
to improve the quality of drug therapeutics. Clinical trials play a central role in drug
development. Over time, the clinical trial infrastructure has improved and is now inte-
grating the contribution of clinical research coordinators (CRC). Nevertheless, the atti-
tude of doctors towards clinical trials still favors conventional/historical methodologies. In
the present study, we explored the view of doctors towards clinical trials for drug devel-
opment, in order to improve communication among participants, sponsors, and investigators.
A questionnaire was designed for this pilot study. The questionnaire included general
attitudes, difficult points, the benefit of doctors in participating as investigators, special
attention requirements, and the expected role of CRC in clinical trials for drug approval.
In addition, the appropriate use of the outpatient clinic was examined. The question-
naire was provided to doctors in each department of Tokushima University Hospital in
2000 and 2004. Because of the small number of subjects included in this pilot study, no
statistical analysis is presented.
A total of 89 (81%) and 62 (56%) doctors among 110 responded to the survey in 2000 and 2004,
respectively. Inquiries about the familiarity of the physicians with clinical trials for drug
approval revealed that 84% in 2000 and 66% in 2004 were aware of such trials. The attitude
towards participating as investigators in the clinical trials was favorable, with a re-
sponse of 66% in 2000 and 58% in 2004. Patients’ refusal and the informed consent process
were considered difficult areas by many doctors. Expected roles of CRC included activi-
ties based on the nurse’s specialty. Although many doctors agreed to take care of the study
participants separately from the clinical practice, they lacked the time to do so.
In spite of the doctors’ workload reduction by introduction of the CRC concept, their
views regarding clinical trials for drug approval remain conventional. Further refine-
ment in the support process by CRC should be considered in our hospital, and the views
of the doctors should be investigated in a larger study, in order to promote clinical trials
for drug approval in Japan. J. Med. Invest. 53 : 292-296, August, 2006
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INTRODUCTION
The development of new and useful pharmaceu-
tical drugs is essential to improve the quality of
drug therapeutics. Among the various processes
of drug development, clinical trials play a central
role. Clinical trials in Japan are associated with
certain scientific, ethical, and regulatory problems
(1). Compared to Japan’s contributions in basic
research, clinical research contributions were re-
ported as still unsatisfactory in 2002 (2) ; thus, the
promotion of clinical trials is an important issue in
Japan. As for clinical trials for drug approval by
regulatory agents, the infrastructure is still devel-
oping since the introduction of the Good Clinical
Practice approved by the International Conference
on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use
(ICH) (3) in 1997. Contributions of coordinators to
clinical trials, a common feature of clinical trials
performed in the United States, is now popular in
Japan. Training of clinical research coordinators
(CRC) is emphasized in the plan for promotion of
clinical trials for drug approval by the Ministry of
Health, Labor and Welfare and the Ministry of
Culture and Science of Japan.
In Tokushima University Hospital, an academic
hospital in Shikoku district (710 beds and 160
medical doctors except residents), the Clinical Trial
Center for Developmental Therapeutics was or-
ganized in 1999 as a supporting system for clinical
trials. Four nurses, two pharmacists and one
nutritionist work as CRC and coordinate the com-
munication among participants, sponsors, and
investigators (4). Currently, the new system for
performing clinical trials for drug approval is
being integrated as a standard method. Since a
clear understanding of the attitude of doctors may
contribute to the progress of clinical trials, the
attitude of doctors towards clinical trials for drug
approval was investigated using pilot question-
naires in 2000 and 2004. In the present paper, the
results of these investigations are reported and
discussed.
METHODS
A questionnaire was designed specifically for
this pilot study. The questionnaire started by ex-
amining general attitudes towards clinical trials for
drug approval on a four-point scale (strongly agree,
agree, disagree, and strongly disagree). This was
followed by practical questions, such as difficulties
regarding participation as investigators, areas of
special attention, and the expected role of CRC in
clinical trials for drug approval. An open-ended
question to describe the doctors’ benefits of in-
volvement in clinical trials for drug approval was
also included. In addition, another question con-
cerned the appropriate use of the outpatient clinic.
Lastly, there was an opportunity to give more de-
tailed responses if desired. The questionnaire was
provided to each department of Tokushima Uni-
versity Hospital in 2000 and 2004, excluding the
outpatient clinic question. In order to survey the
attitude of possible principal investigators, about 5-
10 staffs (non-residents) were mainly asked to re-
spond in each department, since principal investi-
gators in clinical trials for drug approval are re-
stricted to staffs in Tokushima University Hospital.
In view of the small number of subjects included
in this pilot study, no statistical analysis of the data
was performed. The results have been used to
improve the activity of CRC in our hospital and to
provide information for the development of future
studies.
RESULTS
Characteristics of questioned doctors
A total of 89 (81%) and 62 (56%) doctors among
110 responded to the survey in 2000 and 2004, re-
spectively. Among the questionnaires, 61 doctors
(69%) in 2000 and 38 doctors (61%) in 2004 had
contributed to clinical trials for drug approval after
1997, the year that the Good Clinical Practice was
implemented in Japan.
General attitudes towards clinical trials fordrugapproval
When questioned regarding feelings about the
clinical trials, 84% in 2000 and 66% in 2004 stated
that they were familiar with clinical trials and the
drug approval process, as shown in Figure 1A.
Regarding the attitude towards participating as
investigators in the clinical trials, 66% in 2000 and
58% in 2004 gave favorable responses (Figure 1B).
One doctor mentioned low confidence in clinical
skills as a reason for hesitating to participate.
Difficult points of investigators participating in clinical
trials for drug approval
Selected answers to this question are shown in
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Figure 2. In 2000, the difficulties were patients’ re-
fusal (77%), informed consent process (64%), cum-
bersome procedures (36%), and reporting of
adverse events (26%). In 2004, the difficulties were
similar, but with different frequencies : patients’
refusal (47%), informed consent process (44%),
cumbersome procedures (47%), and reporting of
adverse events (44%).
Doctors’ benefit of participating as investigators
in clinical trials for drug approval
An open-ended question to describe the benefits
of involvement of doctors in the clinical trials was
added to the survey in 2004. Among 26 doctors who
responded, the benefits were advancement of therapy
(6), close contact with developmental drugs (8),
therapeutic options (4), financial benefits for the
hospital (6), and a chance to come into contact
with clinical trial methodology (2).
Areas that require special attention in clinical trials
for drug approval
In 2000, special attention was devoted to patients’
views (41%), patients’ physical status (43%), view
of the family (20%), doctor-patient relationship
(82%), adverse events (75%), following protocol
(48%), and participant numbers (48%). In 2004,
special attention was devoted to patients’ views
(19%), patients’ physical status (27%), view of the
family (24%), doctor-patient relationship (63%), ad-
verse events (69%), following protocol (27%), and
participant numbers (29%).
Expected role of CRC in clinical trials for drug approval
Regarding the time of support by CRC, 83% and
84% of the responders wanted support throughout
the entire period in 2000 and in 2004, respectively.
When asked about the expected roles of CRC,
doctors selected the following answers. In 2000,
doctors expected support from CRC in obtaining
informed consent (62%), explanation of the medi-
cation schedule (53%), confirmation of the compli-
ance (60%), monitoring of the patients’ views
(56%), follow-up of the physical status (55%), re-
sponse to adverse events (55%), management in
protocol observance (43%), schedule management
(44%), making the case report forms (36%), re-
sponse in monitoring and audit (44%), explaining
the clinical trial itself (37%), and general consulta-
tion of the clinical trial itself (48%). In 2004, the
doctors expected support from CRC in obtaining
informed consent (77%), explanation of the medi-
cation schedule (81%), confirmation of compliance
(48%), monitoring of patients’ view (27%), follow-
up of the physical status (37%), response to ad-
verse events (48%), management in protocol ob-
servance (53%), schedule management (74%), making
the case report forms (69%), response in monitor-
ing and audit (44%), explanation of the clinical trial
itself (37%), and general consultation of the clinical
trial itself (50%).
Favorable use of special outpatient rooms for study
participants
In clinical trials for outpatients in Japan, doctors
generally care for study participants at the same
clinic as ordinary patients. To provide good cir-
cumstances for study participants, our hospital has
a special outpatient room for the participants. In
2004, the doctors were asked about using the special
room. Forty-five (73%) agreed to care for study
Figure 1 : General view of clinical trials for drug approval
(Figure 1A), and the attitude towards participation as investiga-
tors in clinical trials for drug approval (Figure 1B).
Figure 2 : Difficult points of participation of investigators in
clinical trials for drug approval.
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participants separately from their clinical practice.
Twenty-six (42%) agreed to set aside time for
study participants separately from their ordinary
patients, but only 62% of the agreeing physicians
had sufficient time to perform this task.
DISCUSSION
In Japanese clinical trials, investigators once
took a more active role than their counterparts in
the United States (5). Investigators in Japan had to
do virtually everything, from patient care to admin-
istrative work, during the course of the study (6).
It is highly likely that the excessive workload
borne by investigators in Japan had an adverse
effect on the quality of the trials (7) and many doc-
tors considered clinical trials, especially these for
drug approval, an annoyance. Since introducing
the concept of CRC, the workload reduction seems
to have been achieved, if only partly, which is also the
case at Tokushima University Hospital. Nevertheless,
as shown in Figure 1, fewer doctors are familiar
with clinical trials in 2004 than in 2000, and fewer
feel favorable to participate as investigators in
2004 than in 2000. As shown in Figure 2, many
doctors considered cumbersome procedures and
reporting of adverse events problems in the
pursuit of clinical trials. Since contributions of
CRC can be expected in these fields, more refine-
ment in the support process by CRC is necessary.
Nevertheless, the widespread knowledge that
clinical trials have an essentially complicated proc-
ess may make clinical trials less familiar and more
unfavorable.
There is evidently a strong resistance among
the Japanese to be subjects in clinical trials. The
reason for this resistance appears to be multifacto-
rial. The lack of volunteer spirit and, more impor-
tantly, the lack of benefits from participation are
reasons often mentioned (6). In addition, doctors
tend to fear a negative response from patients when
referral to the trial is proposed (8). As shown in
Figure 2, many doctors found difficulty in the patients’
refusal and informed consent process. As reported
by Rahman et al . (9), training, a manual for obtain-
ing informed consent and a face-to-face demon-
stration of patient registration and follow-up proce-
dures for the potential participants could be a
useful tool to overcome this problem.
Based on long-held principles of research ethics,
the central societal purpose of trials is ideally the
advancement of therapy for future patients (10).
Nevertheless, in the mailed survey to oncology
specialists of the United States, Joffe et al . (11)
reported many respondents viewed the main so-
cietal purpose of clinical trials as benefiting the
participants rather than creating general knowl-
edge to advance future therapy. The patient’s per-
ception of personal benefit was the most important
factor in the patient’s decision (12). In the present
study, numerous doctors considered clinical trials
for drug approval as a therapeutic option.
In the United States, the duties of CRC are well
defined (13). In Japan, CRC is still a new concept
and nurses and pharmacists mainly play CRC
roles in addition to their other expected roles. In
Tokushima University Hospital, nurses mainly play
the role of CRC on the basis of nurse specialty
(14). Therefore, the expected roles of CRC include
the activity based on the nurse’s specialty. Further
study is warranted to evaluate the appropriate du-
ties of CRC in Japan.
As part of establishing the infrastructure for clini-
cal trials, creation of an environment in which
patients can easily participate would improve the
quality of clinical trials, in addition to creating out-
patient clinics exclusively for clinical trials (6). In
Tokushima University Hospital, a special outpa-
tient room was prepared for study participants,
and it was used by many doctors. In 2004, the
doctors were asked about the favorable use of the
special room. Although many doctors agreed to
care for the study participants separately from
their clinical practice and 42% of this group wanted
to set aside time for study participants separately
from their ordinary patients, generating the time
to do so was difficult.
In the present article, the view of the doctors
toward clinical trials for drug approval at Tokushima
University Hospital were reported. Because of
significant limitations of this pilot study, the view
of doctors should be expanded in a larger study, in
order to promote clinical trials for drug approval in
Japan. In these studies, the significance of back-
ground, such as specialty and types of past clinical
trial experiences, on the view should be examined.
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